SCHEMBL25878585

SCHEMBL25878585

Cc1cc(Cl)c(C(=O)OC(C)(C)C)c(C)n1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.45
LMNA P02545 3/20 0.42
MAPT P10636 3/20 0.42
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
NPSR1 Q6W5P4 2/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
POLB P06746 2/20 0.37
LCK P06239 1/20 0.36
TP53 P04637 1/20 0.36
KDM4E B2RXH2 1/20 0.35
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25289195 0.87 CNR1 (0.39) KMT2ALMNAMAPTCNR1CNR2
SCHEMBL30496268 0.87 CNR1 (0.39) KMT2ALMNAMAPTCNR1CNR2
SCHEMBL31369008 0.83 KMT2A (0.50) KMT2ALMNAMAPTALDH1A1MAPK1
SCHEMBL30496247 0.81 GPR119 (0.38) KMT2ALMNAMAPTCNR1CNR2
SCHEMBL25282720 0.81 GPR119 (0.38) KMT2ALMNAMAPTCNR1CNR2
SCHEMBL8840383 0.79 POLB (0.57) KMT2ALMNAMAPTNPSR1ALDH1A1
SCHEMBL22866604 0.77 CNR1 (0.44) KMT2ALMNAMAPTCNR1CNR2
SCHEMBL10329947 0.76 SMN1; SMN2 (0.41) KMT2ANPSR1CYP2C9CYP2C19ALDH1A1
SCHEMBL900419 0.75 ALDH1A1 (0.58) KMT2ALMNAMAPTALDH1A1MAPK1
SCHEMBL6652987 0.75 KMT2A (0.45) KMT2ALMNAMAPTNPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219973-A1 DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF USP7, USP28, USP1 KMT2A 884/4885LMNA 3209/4885MAPT 1555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.